Tin Su
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drosophila melanogaster | 29 | 2025 | 233 | 7.290 |
Why?
| | Drosophila Proteins | 23 | 2022 | 204 | 5.360 |
Why?
| | Drosophila | 18 | 2019 | 154 | 4.630 |
Why?
| | Radiation, Ionizing | 12 | 2020 | 80 | 2.360 |
Why?
| | Regeneration | 7 | 2025 | 197 | 2.220 |
Why?
| | Apoptosis | 17 | 2025 | 2553 | 2.150 |
Why?
| | Cell Cycle | 17 | 2020 | 601 | 2.130 |
Why?
| | Mitosis | 12 | 2011 | 192 | 1.580 |
Why?
| | DNA Damage | 15 | 2020 | 420 | 1.520 |
Why?
| | Caspases | 4 | 2020 | 247 | 1.490 |
Why?
| | Imaginal Discs | 5 | 2019 | 5 | 1.390 |
Why?
| | Wings, Animal | 7 | 2022 | 34 | 1.280 |
Why?
| | Wnt1 Protein | 3 | 2022 | 8 | 1.270 |
Why?
| | Cell Cycle Proteins | 11 | 2017 | 617 | 1.190 |
Why?
| | Animals | 64 | 2025 | 36940 | 1.170 |
Why?
| | Tumor Suppressor Protein p53 | 6 | 2020 | 528 | 1.130 |
Why?
| | Vaccines | 2 | 2023 | 406 | 1.110 |
Why?
| | Protein Synthesis Inhibitors | 2 | 2025 | 47 | 1.090 |
Why?
| | Neoplasms | 7 | 2025 | 2671 | 1.080 |
Why?
| | STAT Transcription Factors | 2 | 2017 | 17 | 1.070 |
Why?
| | High-Throughput Screening Assays | 2 | 2023 | 158 | 1.030 |
Why?
| | Stem Cells | 3 | 2018 | 594 | 0.960 |
Why?
| | Protein Biosynthesis | 3 | 2025 | 433 | 0.950 |
Why?
| | Chromosomes | 3 | 2024 | 107 | 0.940 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 259 | 0.900 |
Why?
| | Loss of Heterozygosity | 2 | 2024 | 51 | 0.900 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2129 | 0.880 |
Why?
| | Cell Death | 5 | 2018 | 374 | 0.840 |
Why?
| | Head and Neck Neoplasms | 3 | 2025 | 606 | 0.840 |
Why?
| | Radiation Tolerance | 3 | 2014 | 96 | 0.830 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2015 | 43 | 0.820 |
Why?
| | Hematologic Neoplasms | 1 | 2025 | 156 | 0.810 |
Why?
| | Spindle Apparatus | 7 | 2011 | 102 | 0.810 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 92 | 0.800 |
Why?
| | Larva | 8 | 2022 | 226 | 0.780 |
Why?
| | Models, Biological | 11 | 2020 | 1783 | 0.770 |
Why?
| | Drug Discovery | 2 | 2023 | 142 | 0.760 |
Why?
| | DNA Replication | 4 | 2010 | 238 | 0.720 |
Why?
| | Embryo, Nonmammalian | 6 | 2011 | 167 | 0.710 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 455 | 0.690 |
Why?
| | Autophagy | 2 | 2024 | 284 | 0.680 |
Why?
| | Gene Expression Profiling | 2 | 2022 | 1774 | 0.680 |
Why?
| | DNA Repair | 6 | 2020 | 231 | 0.670 |
Why?
| | Wound Healing | 1 | 2023 | 331 | 0.670 |
Why?
| | Transcription Factors | 4 | 2022 | 1719 | 0.640 |
Why?
| | Tumor Suppressor Proteins | 3 | 2021 | 327 | 0.640 |
Why?
| | Glioblastoma | 1 | 2023 | 345 | 0.640 |
Why?
| | Peptide Hydrolases | 1 | 2020 | 111 | 0.630 |
Why?
| | Salivary Glands | 1 | 2019 | 33 | 0.620 |
Why?
| | Gastrula | 3 | 2004 | 17 | 0.610 |
Why?
| | Drugs, Investigational | 1 | 2019 | 33 | 0.610 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 184 | 0.590 |
Why?
| | Pyrophosphatases | 1 | 2017 | 28 | 0.550 |
Why?
| | Teaching | 2 | 2011 | 224 | 0.550 |
Why?
| | Nuclear Proteins | 4 | 2009 | 712 | 0.550 |
Why?
| | E2F1 Transcription Factor | 2 | 2024 | 64 | 0.540 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 872 | 0.540 |
Why?
| | Gene Expression Regulation, Developmental | 7 | 2022 | 860 | 0.530 |
Why?
| | Microtubule-Associated Proteins | 2 | 2009 | 196 | 0.510 |
Why?
| | Models, Animal | 1 | 2017 | 384 | 0.490 |
Why?
| | Signal Transduction | 7 | 2024 | 5079 | 0.490 |
Why?
| | Disease Models, Animal | 5 | 2020 | 4295 | 0.470 |
Why?
| | Protein Kinases | 5 | 2021 | 319 | 0.460 |
Why?
| | MicroRNAs | 2 | 2014 | 692 | 0.450 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 194 | 0.450 |
Why?
| | Research | 1 | 2017 | 451 | 0.440 |
Why?
| | Methyl Methanesulfonate | 3 | 2010 | 7 | 0.440 |
Why?
| | Phosphorylation | 8 | 2025 | 1759 | 0.440 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2009 | 434 | 0.440 |
Why?
| | Mutation | 13 | 2020 | 3958 | 0.420 |
Why?
| | Epithelial Cells | 2 | 2017 | 1096 | 0.410 |
Why?
| | Mutagens | 3 | 2010 | 22 | 0.410 |
Why?
| | Heterozygote | 3 | 2024 | 293 | 0.410 |
Why?
| | DNA-Binding Proteins | 7 | 2022 | 1502 | 0.410 |
Why?
| | Genome, Insect | 1 | 2012 | 23 | 0.380 |
Why?
| | Neuropeptides | 2 | 2009 | 73 | 0.380 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3412 | 0.370 |
Why?
| | Students | 2 | 2023 | 622 | 0.370 |
Why?
| | Chromosome Aberrations | 2 | 2024 | 156 | 0.360 |
Why?
| | Cell Survival | 5 | 2024 | 1120 | 0.360 |
Why?
| | Cell Proliferation | 7 | 2025 | 2475 | 0.360 |
Why?
| | Cyclin A | 2 | 2001 | 17 | 0.360 |
Why?
| | Maytansine | 1 | 2011 | 16 | 0.360 |
Why?
| | Cancer Vaccines | 2 | 2025 | 172 | 0.350 |
Why?
| | DNA, Satellite | 1 | 2010 | 18 | 0.350 |
Why?
| | Educational Measurement | 2 | 2011 | 289 | 0.350 |
Why?
| | Hydrozoa | 1 | 2010 | 1 | 0.340 |
Why?
| | Paclitaxel | 1 | 2012 | 230 | 0.340 |
Why?
| | E2F2 Transcription Factor | 1 | 2010 | 15 | 0.340 |
Why?
| | Cell Division | 3 | 2005 | 794 | 0.340 |
Why?
| | Adjuvants, Immunologic | 2 | 2023 | 226 | 0.340 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 180 | 0.340 |
Why?
| | Membrane Proteins | 1 | 2017 | 1164 | 0.340 |
Why?
| | Peer Group | 2 | 2011 | 242 | 0.340 |
Why?
| | Heterochromatin | 1 | 2010 | 53 | 0.330 |
Why?
| | Humans | 33 | 2025 | 137585 | 0.330 |
Why?
| | Piperazines | 2 | 2024 | 350 | 0.330 |
Why?
| | Biology | 1 | 2011 | 88 | 0.320 |
Why?
| | Genetics | 1 | 2009 | 23 | 0.300 |
Why?
| | Tyrosine | 1 | 2009 | 222 | 0.300 |
Why?
| | Leprosy | 2 | 2019 | 24 | 0.290 |
Why?
| | Learning | 2 | 2011 | 409 | 0.290 |
Why?
| | CDC2 Protein Kinase | 3 | 2005 | 31 | 0.290 |
Why?
| | Cyclin E | 2 | 2007 | 25 | 0.290 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1236 | 0.280 |
Why?
| | Metaphase | 3 | 2005 | 31 | 0.280 |
Why?
| | Anaphase | 3 | 2005 | 18 | 0.280 |
Why?
| | Immunotherapy | 2 | 2025 | 641 | 0.280 |
Why?
| | Cell Movement | 2 | 2019 | 967 | 0.270 |
Why?
| | Mice | 9 | 2025 | 17787 | 0.250 |
Why?
| | Genes, cdc | 3 | 2006 | 11 | 0.240 |
Why?
| | Gene Expression Regulation | 3 | 2009 | 2607 | 0.230 |
Why?
| | Telomere | 2 | 2006 | 280 | 0.230 |
Why?
| | Chromosomal Instability | 1 | 2004 | 19 | 0.230 |
Why?
| | Cisplatin | 2 | 2024 | 320 | 0.220 |
Why?
| | MAP Kinase Signaling System | 3 | 2024 | 320 | 0.220 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2004 | 18 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 139 | 0.220 |
Why?
| | Tubulin | 1 | 2005 | 144 | 0.220 |
Why?
| | Peroxiredoxins | 1 | 2024 | 24 | 0.220 |
Why?
| | Arthropods | 1 | 2004 | 9 | 0.220 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2003 | 4 | 0.210 |
Why?
| | Alleles | 3 | 2020 | 891 | 0.210 |
Why?
| | Curriculum | 1 | 2011 | 992 | 0.210 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2023 | 11 | 0.210 |
Why?
| | Radioimmunotherapy | 1 | 2023 | 16 | 0.210 |
Why?
| | Pyrimidinones | 1 | 2024 | 113 | 0.210 |
Why?
| | Vertebrates | 1 | 2004 | 60 | 0.210 |
Why?
| | Flow Cytometry | 3 | 2022 | 1178 | 0.210 |
Why?
| | Organogenesis | 1 | 2003 | 58 | 0.200 |
Why?
| | Albumins | 1 | 2023 | 114 | 0.200 |
Why?
| | Cytoskeleton | 1 | 2004 | 191 | 0.200 |
Why?
| | Telomere-Binding Proteins | 1 | 2004 | 122 | 0.200 |
Why?
| | Pyridones | 1 | 2024 | 168 | 0.200 |
Why?
| | Gene Expression | 2 | 2018 | 1502 | 0.190 |
Why?
| | Immunoprecipitation | 3 | 2009 | 155 | 0.190 |
Why?
| | Cell Line | 4 | 2023 | 2847 | 0.190 |
Why?
| | Cell Separation | 2 | 2022 | 318 | 0.190 |
Why?
| | Antigens, Neoplasm | 2 | 2025 | 319 | 0.180 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2001 | 72 | 0.180 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 325 | 0.180 |
Why?
| | Neurofibromin 2 | 2 | 2021 | 3 | 0.180 |
Why?
| | Checkpoint Kinase 2 | 4 | 2010 | 29 | 0.180 |
Why?
| | Cell Plasticity | 1 | 2022 | 35 | 0.180 |
Why?
| | Lymph Nodes | 1 | 2023 | 491 | 0.170 |
Why?
| | Blotting, Western | 4 | 2009 | 1226 | 0.170 |
Why?
| | Pyridines | 1 | 2024 | 506 | 0.170 |
Why?
| | Phthalazines | 1 | 2020 | 45 | 0.170 |
Why?
| | Cetuximab | 1 | 2020 | 98 | 0.170 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 50 | 0.170 |
Why?
| | Intracellular Space | 1 | 2020 | 68 | 0.170 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 30 | 0.160 |
Why?
| | RNA Interference | 3 | 2019 | 469 | 0.160 |
Why?
| | Perception | 1 | 2022 | 359 | 0.160 |
Why?
| | Biological Evolution | 1 | 2004 | 474 | 0.160 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 188 | 0.160 |
Why?
| | Diacylglycerol Kinase | 1 | 2019 | 5 | 0.160 |
Why?
| | rac GTP-Binding Proteins | 1 | 2019 | 32 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 389 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1079 | 0.160 |
Why?
| | DNA | 2 | 2005 | 1459 | 0.150 |
Why?
| | Radiobiology | 1 | 2019 | 6 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 115 | 0.150 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 232 | 0.150 |
Why?
| | Embryonic Development | 1 | 2000 | 119 | 0.150 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2000 | 172 | 0.150 |
Why?
| | Molecular Imaging | 1 | 2019 | 56 | 0.150 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2018 | 162 | 0.150 |
Why?
| | Checkpoint Kinase 1 | 4 | 2006 | 30 | 0.150 |
Why?
| | Transients and Migrants | 1 | 2017 | 24 | 0.140 |
Why?
| | Phenotype | 3 | 2018 | 3196 | 0.140 |
Why?
| | S Phase | 2 | 2010 | 77 | 0.140 |
Why?
| | Gene Silencing | 2 | 2016 | 195 | 0.140 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 434 | 0.140 |
Why?
| | Protein Transport | 1 | 2018 | 445 | 0.130 |
Why?
| | Cell Lineage | 1 | 2018 | 350 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2019 | 363 | 0.130 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 22 | 0.130 |
Why?
| | Cell Polarity | 1 | 2017 | 141 | 0.120 |
Why?
| | Cells, Cultured | 2 | 2019 | 4193 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5472 | 0.120 |
Why?
| | Receptors, TIE | 1 | 2015 | 1 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 399 | 0.120 |
Why?
| | Cost of Illness | 1 | 2017 | 308 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 5778 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3284 | 0.110 |
Why?
| | Genetic Testing | 1 | 2017 | 460 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 2 | 2005 | 390 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 283 | 0.110 |
Why?
| | Morphogenesis | 2 | 2005 | 166 | 0.110 |
Why?
| | HeLa Cells | 1 | 2015 | 636 | 0.110 |
Why?
| | Time Factors | 5 | 2005 | 6828 | 0.110 |
Why?
| | Cyclin-Dependent Kinases | 2 | 2004 | 132 | 0.100 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2020 | 141 | 0.100 |
Why?
| | X-Rays | 2 | 2004 | 28 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 806 | 0.090 |
Why?
| | Brain | 1 | 2004 | 2668 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2253 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 24 | 0.090 |
Why?
| | Drug Synergism | 2 | 2024 | 382 | 0.090 |
Why?
| | Embryology | 1 | 2011 | 1 | 0.090 |
Why?
| | HCT116 Cells | 1 | 2011 | 80 | 0.090 |
Why?
| | Glioma | 1 | 2015 | 395 | 0.090 |
Why?
| | Tuberous Sclerosis | 1 | 2011 | 55 | 0.090 |
Why?
| | Mice, Nude | 2 | 2024 | 698 | 0.090 |
Why?
| | Mitotic Index | 1 | 2010 | 25 | 0.090 |
Why?
| | Cyclins | 2 | 2001 | 91 | 0.080 |
Why?
| | Drug Design | 1 | 2011 | 167 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1077 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 767 | 0.080 |
Why?
| | Green Fluorescent Proteins | 2 | 2008 | 390 | 0.080 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 144 | 0.080 |
Why?
| | Goals | 1 | 2011 | 170 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 2003 | 2139 | 0.080 |
Why?
| | Cell Nucleus | 2 | 2003 | 620 | 0.080 |
Why?
| | Male | 7 | 2022 | 67762 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2009 | 375 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 2003 | 2900 | 0.070 |
Why?
| | Biological Products | 1 | 2012 | 216 | 0.070 |
Why?
| | Female | 10 | 2025 | 73304 | 0.070 |
Why?
| | Gene Deletion | 2 | 2015 | 391 | 0.070 |
Why?
| | Kinetochores | 1 | 2008 | 53 | 0.070 |
Why?
| | China | 2 | 2019 | 217 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1325 | 0.070 |
Why?
| | Xenopus | 2 | 2005 | 87 | 0.070 |
Why?
| | Gene Dosage | 1 | 2008 | 140 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 145 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 4149 | 0.070 |
Why?
| | E2F Transcription Factors | 1 | 2007 | 60 | 0.070 |
Why?
| | Quality of Life | 1 | 2019 | 2892 | 0.070 |
Why?
| | Comprehension | 1 | 2009 | 172 | 0.070 |
Why?
| | Nanoparticles | 2 | 2025 | 481 | 0.070 |
Why?
| | Cytokinesis | 1 | 2007 | 48 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1238 | 0.060 |
Why?
| | Gastrin-Releasing Peptide | 1 | 2005 | 7 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2005 | 402 | 0.060 |
Why?
| | Chromatography, Affinity | 1 | 2005 | 88 | 0.060 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 114 | 0.060 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2006 | 43 | 0.060 |
Why?
| | Centrosome | 1 | 2005 | 71 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 6 | 0.060 |
Why?
| | Transgenes | 1 | 2005 | 180 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 810 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2004 | 28 | 0.060 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2004 | 66 | 0.060 |
Why?
| | Models, Genetic | 2 | 2006 | 600 | 0.060 |
Why?
| | Melanoma, Experimental | 1 | 2025 | 114 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2012 | 2833 | 0.050 |
Why?
| | Cleavage Stage, Ovum | 1 | 2004 | 5 | 0.050 |
Why?
| | Egg Proteins | 1 | 2004 | 17 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2024 | 124 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2004 | 97 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 812 | 0.050 |
Why?
| | Retinoblastoma Protein | 1 | 2004 | 57 | 0.050 |
Why?
| | Invertebrates | 1 | 2004 | 23 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 79 | 0.050 |
Why?
| | Gene Targeting | 1 | 2004 | 81 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2004 | 39 | 0.050 |
Why?
| | Fertilization | 1 | 2004 | 44 | 0.050 |
Why?
| | Macromolecular Substances | 1 | 2004 | 229 | 0.050 |
Why?
| | X Chromosome | 1 | 2003 | 53 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2004 | 93 | 0.050 |
Why?
| | Crosses, Genetic | 1 | 2003 | 137 | 0.050 |
Why?
| | Substrate Specificity | 1 | 2004 | 372 | 0.050 |
Why?
| | Body Patterning | 1 | 2004 | 132 | 0.050 |
Why?
| | Protective Factors | 1 | 2023 | 93 | 0.050 |
Why?
| | Sequence Alignment | 1 | 2003 | 343 | 0.050 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 385 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 976 | 0.050 |
Why?
| | DNA Transposable Elements | 1 | 2003 | 121 | 0.050 |
Why?
| | Mammals | 1 | 2004 | 283 | 0.050 |
Why?
| | Fertility | 1 | 2003 | 160 | 0.050 |
Why?
| | Recombination, Genetic | 1 | 2003 | 204 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2005 | 739 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2003 | 570 | 0.050 |
Why?
| | Telomerase | 1 | 2004 | 250 | 0.050 |
Why?
| | 14-3-3 Proteins | 1 | 2001 | 18 | 0.050 |
Why?
| | Insect Proteins | 1 | 2001 | 39 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 465 | 0.040 |
Why?
| | Health Surveys | 1 | 2023 | 514 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 622 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2001 | 225 | 0.040 |
Why?
| | Cytoplasm | 1 | 2001 | 274 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 1 | 2005 | 557 | 0.040 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 20 | 0.040 |
Why?
| | Ubiquitination | 1 | 2021 | 102 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2020 | 78 | 0.040 |
Why?
| | Temperature | 1 | 2004 | 679 | 0.040 |
Why?
| | Blastoderm | 1 | 2000 | 1 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 15 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 265 | 0.040 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 164 | 0.040 |
Why?
| | Proteolysis | 1 | 2021 | 177 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2000 | 67 | 0.040 |
Why?
| | Cell Size | 1 | 2000 | 91 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2000 | 150 | 0.040 |
Why?
| | Base Sequence | 1 | 2003 | 2181 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1738 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 268 | 0.040 |
Why?
| | Heat-Shock Response | 1 | 2000 | 77 | 0.040 |
Why?
| | Cell Count | 1 | 2000 | 324 | 0.040 |
Why?
| | Phylogeny | 1 | 2003 | 904 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 801 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 125 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 218 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 2057 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2025 | 900 | 0.040 |
Why?
| | Histones | 1 | 2004 | 636 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 225 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 916 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 249 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.030 |
Why?
| | Microscopy | 1 | 2019 | 152 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 614 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2004 | 3015 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2020 | 483 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2734 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1468 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2000 | 528 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2015 | 12 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1692 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2224 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1396 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1457 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5757 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1996 | 0.020 |
Why?
| | Middle Aged | 2 | 2019 | 33479 | 0.020 |
Why?
| | Adult | 2 | 2019 | 37929 | 0.010 |
Why?
| | Xenopus Proteins | 1 | 2005 | 37 | 0.010 |
Why?
| | G2 Phase | 1 | 2005 | 38 | 0.010 |
Why?
| | Hydroxyurea | 1 | 2005 | 35 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 272 | 0.010 |
Why?
| | Adolescent | 1 | 2023 | 21513 | 0.010 |
Why?
| | RNA-Binding Proteins | 1 | 2006 | 422 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 13209 | 0.010 |
Why?
| | Aged | 1 | 2019 | 23961 | 0.010 |
Why?
| | RNA | 1 | 2005 | 921 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|